Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ivax/Serono Oral MS Therapy Mylinax Efficacy Trials Planned For 2004

Executive Summary

Ivax and Serono hope to launch pivotal trials for their oral multiple sclerosis therapy Mylinax (cladribine) in late 2004
Advertisement

Related Content

Elan Meltdown May End R&D Joint Ventures As Funding Vehicle For Biotech
Teva Oral Copaxone Could Be Studied At Higher Dose After Interim Analysis
R.W. Johnson Mylinax
R.W. Johnson Mylinax
Advertisement
UsernamePublicRestriction

Register

PS043624

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel